Invega was first approved by the FDA in December 2006, and costs about $397 without insurance for a supply of 30 oral, extended release 1.5 mg tables
Bosch-Barrera J, Gaztaaga M, and Ceballos J, et al (2009) Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer Onkologie 32 580584 PMID: 19816075 4
"Professional and kind." A.M
The science shows all approved sites are effective
This consumer-friendly approach has its advantages - the process is fast, intuitive, and low-friction - and its potential downsides, as some patients and healthcare commentators have noted that the simplified experience may make the prescribing process feel somewhat transactional
Verification Standard Verification Standard